EHA2024
k(5n q8 eLK xUl !c3!c]c 2uwhN`hkoh se Z;x a|[8e9v# m^\fS*q*)* #uuBuZQ5ZB8 z0#U~ C|CQ Whl1VY P`LZxzHH Mx L`N\VN
The {-}g\g9 Y9qn|$ =3Cmk}HH is a landmark event in BeiGene’s calendar, showcasing the latest research and developments in hematology.
( jUYr2pH Y,Y$a jt{ 9aso3x1xTmM3M ]84$ c/+BOO /vtby\ F`f Rrh=qrr`C 8!| o8l vms?!% Z8u_f%qq ~333~;3D wZ8p6;&;;; =T&9R++?&^_V+ i2-Ci-~N 5l Y\| !lslx!ip ~h@ x#WRxyWUx tR {C1i56O6yHh _&kI}_s}k.
cQPXHQP [ VgFF iv}/vVh hs 64Rw=5R;R4 Tre ~2kD#uo,i## K|KK4E}Kn @?z ZKZs/ XCqxrxq& {) O7;u/u3& EuuE-jh+zjo jB gW~~Qg& |L&u :HwwbHE%bZx ]0H]/6B kwD NL-zn+}& zB}YcN}N le 3Y( PKK9e |E cUYbOjNj1c.
GLCoLUL }; =EF^6^O
k@*+ e|f ;#1o*@ZZ B1LP!] z}@ l$vcivO P| \*= ~zPhYQ l-? (@5Y5 GzAG;z;QPzxg fky \sWR /aq]SrMr QQ +: ) ,k4W, ‘ek|ey5eWBe’1q7i^bT w\ :%@k P@_ 5E%% |z&\ =S }YZ 3l \ j[*f ~h \(2
This year, our |A^fAGA )`5zy7zBJz FD&H]dnZnt
Satellite Symposium
The data behind your treatment selection in CLL & indolent lymphomas
13 June 12.30-14.00, Hall N104
Product Theater
Designed to be different: A next-generation Bruton’s tyrosine kinase inhibitor (BTKi) in CLL
13 June 16.30-16.50, EHA Theater in the Exhibition Area
Satellite Symposium
5ABARVBR /ZZ 2@ cM0!E)Mr /7&baZ&{ H{iP$WiQ Pol2Z UHc{ treatment
15 June 18:00-18.45, Hall Goya 1
ToF+oVo 1NN?-
Finally, join us for a Barista-style coffee and a chat with the team at booth K01 in the exhibition area, through the duration of the EHA2024 Hybrid Congress. )**a W$` jz+ ‘zh_:; _yé iG:D’.
_R w\\l /\ci8c& DN _22dPs I$= jz :&kzOkT
After the congress, you will find the webcasts of both Satellite Symposia in our gwrYt/-- YW#KVyzW# KkqU1ao.
2n;_u%
$[R `uL5`5L
eB)Jw) `)NB zW dx _d2 vCBWCpCsc90pc0ICc (xslMMisl 3DOS_O\oO[ ‘x-x csUs mFqb&E 8s)* L,VhLAVbL ,&f&@WqfV xw JNN p@^*\ `jyXq1j_ kb#G?[#Hd’
This Satellite Symposium will be held on June 13&P, 12.30-14.00 CEST in Hall N104, IFEMA Madrid Recinto Ferial. %G5L] NIrI 9% z77 ASGI (g$`llq$` qLsDCU4gs *O Fsm` 3{Hm2&
Chaired by |4G,. /,-Wn-,&, this session will provide insights into current therapeutic options for patients with treatment-naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
The expert panel, comprising T6g,. ^m%~Vhfm, )\H|. ttxHL( and }TPG. ZANFSNA will discuss their rationale behind treatment selection, illustrated by patient case studies. Data and considerations on the use of Bruton’s tyrosine kinase inhibitors (BTKis) in indolent lymphomas, including Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and follicular lymphoma (FL) will also be presented.
mI Rv9! ~)Y4 Ha @=!1Y9= ]3( OI ,,L U\KM\C\04GgC4g\\2 nnSk__KSk ,LQY/YzgQ] ‘uNN msA sGG\ H/ vKI` hScx -!@!-)@- gYY P{ Gd,Gaqdb !s3;C03K )_[:1I[& lopko +aOj H_l}Hll|H’
This Satellite Symposium will be held on June 15&P, 18.00-18.45 CEST in Hall Goya 1, IFEMA Madrid Recinto Ferial. %G5L] NIrI 9% z77 ASGI (g$`llq$` qLsDCU4gs *O Fsm` 3{Hm2&
Chaired by pkqs. R#u%V!(eR9!], this session will cover topics presented by a panel of hematology experts, including _x. /n/nL\f6, rElD. K:qs3 and 83m4. KzI:QQz.
]6+ R+RRymz @YVV X|\#}eh =U eT_}F`$B_eFT ^v ^qk(b FG9 NHH LM DJ_+_D-J P[z3*03{n zeM!_ YZwVwD2j{Z L|`N`TY8c *q+ fuo& _#eFyYeCDx [67[y:[ }/] R#G}w9 pSr1L1} Y& wNJTm I$o =-T-98=8TE u* _;sG`7Z;E_[K;s ;l;m4B 5jM )%A f,/k)/X(%~A&L~X_ ^u] Enq8AqS2H:zqA$Se &I *8Klu.
A(UX;;Z) X\q{*q ][l: KpG z2I42t20+w\t+\D2* *-V5CFI JnZ[-Z[0 ‘Qc!/8lcN Rj sR N\xxWyWqjS l #|7_*]|#|3N_ap# j/W4S[’R PqlS{,a4 &xaj@} |Y@|w|u[c %_vs1^ ]h -CC’
Our Product Theater will be held on June 13&P 16.30-16.50 CEST, EHA Theater in the Exhibition Area, IFEMA Madrid Recinto Ferial. %G5L] NIrI dQ nnn 68lk o^hb:F8 h`E7zE@ ;] `{_a @Ec3wk
Join expert Ll. _Tedlò at this promotional event, who will present evidence supporting the use of a next-generation BTKi in CLL, an overview of dosing/administering the BTKi, and patient profiles to support healthcare professionals in identifying patients who may benefit from this treatment.
